HLS
vs
S&P/ASX 300

Over the past 5 years, HLS has underperformed S&P/ASX 300, delivering a return of -46% compared to the S&P/ASX 300's 22% growth.

Stocks Performance
HLS vs S&P/ASX 300

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Performance Gap
HLS vs S&P/ASX 300

Performance Comparison
HLS vs S&P/ASX 300

1 Month 3 Months 6 Months 1 Year 5 Years 10 Years 20 Years
HLS
Healius Ltd
-2%
-24%
-4%
-17%
-46%
-62%
-28%
S&P/ASX 300
Market Index
-3%
-1%
6%
7%
22%
51%
99%

Healius Ltd
Glance View

Market Cap
994.8m AUD
Industry
Health Care

Healius Ltd. engages in the provision of healthcare technology solutions. The company is headquartered in Sydney, New South Wales and currently employs 11,000 full-time employees. The firm operates through three segments: Pathology, Imaging and Day Hospitals. Pathology segment provides pathology services. Imaging segment offers imaging and scanning services from imaging sites, hospitals and from within the consolidated entity's medical centers. Day Hospitals segment is an operator of day hospitals and hematology or oncology services and provides services and facilities to In-Vitro Fertilization (IVF) specialists. The firm also provides facilities and support services to general practitioners, radiologists and a range of other healthcare professionals, enabling them to care their patients in partnership with the Company's pathologists, nurses and other employees.

HLS Intrinsic Value
2.61 AUD
Undervaluation 48%
Intrinsic Value
Price
H

See Also

Back to Top